Modulation of irinotecan metabolism by ketoconazole

Journal of Clinical Oncology

Volumn 20, Issue 14, 2002, Pages 3122-3129

  Kehrer, Diederik F S ^a   Mathijssen, Ron H J ^a   Verweij, Jaap ^a   de Bruijn, Peter ^a   Sparreboom, Alex ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

7 ETHYL 10 [4 N (5 AMINOPENTANOIC ACID) 1 PIPERIDINO]CARBONYLOXYCAMPTOTHECIN; 7 ETHYL 10 HYDROXYCAMPTOTHECIN; CAMPTOTHECIN DERIVATIVE; CYTOCHROME P450 3A4; DRUG METABOLITE; IRINOTECAN; KETOCONAZOLE; UNCLASSIFIED DRUG;

ADVANCED CANCER; AREA UNDER THE CURVE; ARTICLE; CANCER PATIENT; CLINICAL ARTICLE; CLINICAL TRIAL; COLORECTAL CANCER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DRUG CLEARANCE; DRUG DETERMINATION; DRUG INDUCED DISEASE; DRUG METABOLISM; ENZYME INHIBITION; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

ADULT; AGED; ANTIFUNGAL AGENTS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; CAMPTOTHECIN; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; COLORECTAL NEOPLASMS; CROSS-OVER STUDIES; CYTOCHROME P-450 ENZYME SYSTEM; DRUG ADMINISTRATION SCHEDULE; ENZYME INHIBITORS; FEMALE; HUMANS; KETOCONAZOLE; LEUKOCYTE COUNT; LEUKOCYTES; LIVER; MALE; MIDDLE AGED; MIXED FUNCTION OXYGENASES; NEUTROPHILS; PRODRUGS;

EID: 0037099535     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2002.08.177     Document Type: Article

References (40)

1. Incidence of adverse drug reactions in hospitalized patients: A meta-analysis of prospective studies
2. Drug combinations: Dangerous liaisons or great expectations?
3. Clinical trial design: Incorporation of pharmacokinetic, pharmacodynamic and pharmacogenetic principles
4. Polymorphic human cytochrome P450 enzymes: An opportunity for individualized drug treatment
5. Effects of the antifungal agents on oxidative drug metabolism: Clinical relevance
6. Irinotecan in the treatment of colorectal cancer: Clinical overview
7. Clinical pharmacokinetics and metabolism of irinotecan (CPT-11)
8. Factors involved in prolongation of the terminal disposition phase of SN-38
9. Modulation of irinotecan-induced diarrhea by co-treatment with neomycin in cancer patients
10. Irinotecan (CPT-11) metabolism and disposition in cancer patients
11. Liquid chromatographic determination of irinotecan and three major metabolites in human plasma, urine and feces
12. Femtomole quantitation of 7-ethyl-10-hydroxycamptothecine (SN-38) in plasma samples by reversed-phase high-performance liquid chromatography
13. Pharmacokinetic, metabolic, and pharmaco-dynamic profiles in a dose-escalating study of irinotecan and cisplatin
14. Pharmacokinetic interrelationships of irinotecan (CPT-11) and its three major plasma metabolites in patients enrolled in phase I/II trials
15. Liquid chromatographic determination of ketoconazole, a potent inhibitor of CYP3A4-mediated metabolism
16. Proficient metabolism of irinotecan by a human intestinal carboxylesterase
17. Linearization of the Bradford protein assay increases its sensitivity: Theoretical and experimental studies
18. Metabolism of irinotecan (CPT-11) by human hepatic microsomes: Participation of cytochrome P-450 3A and drug interactions
19. Determination of irinotecan (CPT-11) and its active metabolite SN-38 in human plasma by reversed-phase high-performance liquid chromatography with fluorescence detection
20. Active transepithelial transport of irinotecan (CPT-11) and its metabolites by human intestinal Caco-2 cells
21. Epithelial transport of drugs in cell culture: I. A model for studying the passive diffusion of drugs over intestinal absorptive (Caco-2) cells
22. Reversal of resistance by GF120918 in cell lines expressing the ABC half-transporter, MXR
23. Metabolism of SN-38 by CYP3A4 and microsomes from human liver (HLM)
24. Caco-2 monolayers in experimental and theoretical predictions of drug transport
25. The HER tyrosine kinase inhibitor CI1033 enhances cytotoxicity of 7-ethyl-10-hydroxycamptothecin and topotecan by inhibiting breast cancer resistance protein-mediated drug efflux
26. Subcellular localization and distribution of the breast cancer resistance protein transporter in normal human tissues
27. Pharmacological inhibition of P-glycoprotein transport enhances the distribution of HIV-1 protease inhibitors into brain and testes
28. Modulation of camptothecin analogs in the treatment of cancer: A review
29. Pharmacokinetic modulation of irinotecan and metabolites by cyclosporin A
30. A phase I study of irinotecan (CPT-11) with pharmacokinetic modulation by cyclosporine A (CSA) and phenobarbital (PB)
31. Characterization of CPT-11 hydrolysis by human liver carboxylesterase isoforms hCE1 and hCE2
32. Genetic predisposition to the metabolism of irinotecan (CPT-11): Role of uridine glucuronosyltransferase isoform IA1 in the glucuronidation of its active metabolite (SN-38) in human liver microsomes
33. Polymorphisms of UDP-glucuronosyltransferase gene and irinotecan toxicity: A pharmacogenetic analysis
34. UGT1A1* 28 polymorphism as a determinant of irinotecan disposition and toxicity
35. Sequence diversity in CYP3A promotors and characterization of the genetic basis of polymorphic CYP3A5 expression
36. Metabolism of irinotecan (CPT-11) by CYP3A4 and CYP3A5 in humans
37. Cyclosporin and ketoconazole, drug interaction or therapeutic association?
38. Modulation of irinotecan (CPT-11) toxicity and pharmacokinetics by cyclosporine and phenobarbital
39. Overexpression of a rabbit liver carboxylesterase sensitizes human tumor cells to CPT-11
40. CPT-11 converting carboxylesterase and topoisomerase activities in tumour and normal colon and liver tissues